BRIEF COMMUNICATION |
|
Year : 2017 | Volume
: 6
| Issue : 2 | Page : 68-69 |
|
Dexrazoxane in anthracycline cardiotoxicity
Abhijit S Nair
Department of Anaesthesia and Pain Medicine, Basavatarakam Indo American Cancer Hospital and Research Centre, Hyderabad, Telangana, India
Correspondence Address:
Abhijit S Nair Department of Anaesthesia and Pain Medicine, Basavatarakam Indo American Cancer Hospital and Research Centre, Hyderabad - 500 034, Telangana India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2250-3528.203533
|
|
Anthracycline group of antineoplastic agents is notorious for causing cumulative dose induced cardiotoxicity which is more pronounced in elderly patients and in patients with preexisting cardiac comorbidities. Several preventive strategies have been explored with variable success and without randomized studies and insufficient data. Dexrazoxane is an ethylenediaminetetraacetic acid analog which has been found to be effective when used before or along with anthracycline infusion. The drug is also found to be useful in counteracting injuries caused due to anthracycline extravasation in the tissues. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|